{"disease":{"id":"non-hematologic-malignancies","name":"non hematologic malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00830869","title":"A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01454076","title":"Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01899053","title":"A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02327169","title":"A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01705483","title":"A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT05371054","title":"Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00358163","title":"Trial of PTK787/ZK 222584 Plus Paclitaxel","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}